Corticobasal syndrome (CBS) is a neurodegenerative clinical syndrome frequently linked to a 4-repeat tauopathy. Prior work has identified abnormalities on tau PET, structural MRI, and diffusion MRI (dMRI) in CBS, but the relative sensitivity of these imaging modalities had not been systematically compared. The authors set out to compare the ability of tau PET, regional gray matter volume, and dMRI metrics to discriminate CBS from healthy controls, and to characterize relationships between regional tau uptake, volume loss, and white matter tract abnormalities.
The study included 32 participants meeting criteria for possible or probable CBS and 35 healthy controls. All participants underwent standardized 3T diffusion MRI, 18F-flortaucipir tau PET, and detailed neurologic assessment. The paper reports this as a cross-sectional multimodal imaging comparison; ethical approval was provided by the Mayo Clinic Institutional Review Board. The preprint notes that data supporting the findings are available from the corresponding author upon reasonable request.
Diffusion data were processed using complementary approaches: diffusion tensor imaging (DTI), free-water correction, and Neurite Orientation Dispersion and Density Imaging (NODDI). Tract-level metrics were extracted using the Johns Hopkins University–Eve (JHU EVE) white matter atlas to enable anatomically informed comparisons across participants. Key dMRI metrics emphasized in the report include mean diffusivity (MD) and intracellular volume fraction (ICVF).
Regional gray matter volumes were computed and 18F-flortaucipir standardized uptake value ratios (SUVRs) were calculated to assess tau PET signal. The authors derived a global tau PET uptake measure represented by the first principal component (PC1). A secondary tau analysis removed this global component (PC1-removed tau PET) to evaluate more regionally specific tau signals distinct from a widespread uptake pattern.
The authors assessed discrimination between CBS and controls for each modality using area under the curve (AUC) analyses. Cross-modality relationships were evaluated using regional correlations and covariate-adjusted models that compared volume- and tau-related predictors of white matter abnormalities. The secondary tau analysis (with PC1 removed) was specifically used to determine whether region-specific tau uptake explained white matter changes beyond global tau signal.
Relative to controls, CBS showed widespread increases in MD and reductions in ICVF, most prominently affecting sensorimotor and projection white matter pathways. Structural volume reductions were concentrated in precentral cortex and in subcortical regions including the putamen, thalamus, and pallidum. Abnormalities on flortaucipir tau PET were reported as weaker and less spatially extensive than the diffusion or volume changes.
When modalities were ranked by overall discrimination between CBS and controls, MD showed the strongest performance, followed by ICVF, structural volume, PC1-removed tau PET, and the original tau PET measure including the global component.
In analyses restricted to sensorimotor regions, higher DTI-MD was the imaging measure most strongly associated with lower gray matter volume. The PC1-removed sensorimotor tau uptake was also associated with higher sensorimotor DTI-MD. By contrast, the original (unadjusted) tau uptake and broader cortical or subcortical tau measures were not significant predictors of white matter microstructural abnormalities in these models. These results suggest a closer link between white matter integrity and regional atrophy than between white matter changes and measurable global tau PET uptake.
The study concludes that white matter microstructural disruption is a dominant imaging signature of CBS. Diffusion MRI metrics, particularly mean diffusivity (MD) and intracellular volume fraction (ICVF), provided greater sensitivity for detecting disease-related changes in CBS than either regional gray matter volume loss or flortaucipir tau PET uptake as measured here. The findings imply that dMRI may be the most sensitive modality for detecting CBS-related pathology in vivo and that white matter degeneration is more closely linked to gray matter atrophy than to measurable tau PET signal in this cohort.
This report is a preprint and has not been certified by peer review; the authors explicitly note it should not be used to guide clinical practice. The manuscript states that the Institutional Review Board of Mayo Clinic approved the study and that appropriate participant consent was obtained. The authors declared no competing interests. Data supporting the findings are available from the corresponding author upon reasonable request. The preprint does not provide additional specifics beyond these declarations in the abstract and article information presented.
The work was supported by National Institutes of Health grants listed in the article metadata. Specific grant numbers and funder identifiers were reported in the source. No competing interests were declared by the authors.